SPECIALTY GUIDELINE MANAGEMENT

MARGENZA (margetuximab-cmkb)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Margenza is indicated, in combination with chemotherapy, for the treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of human epidermal growth factor receptor 2 (HER2) status is necessary to initiate the prior authorization review.

III. CRITERIA FOR INITIAL APPROVAL

Breast Cancer

Authorization of 12 months may be granted for treatment of HER2-positive metastatic breast cancer, in combination with chemotherapy, for members who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for breast cancer when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

V. REFERENCES

1. Margenza [package insert]. Rockville, MD: MacroGenics, Inc.; December 2020.

Margenza 4405-A SGM P2020.docx

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

